CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Presence of COVID-19 Compatible CT Abnormalities Clinical Trial

Official title:

CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04512118
• Other study ID #: 2020PI153
• Status: Completed
• Start date: March 15, 2020
• Est. completion date: July 30, 2020

Study information

• Verified date: August 2020
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CT signs that are evocative of lung COVID-19 infections have been extensively described, whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19 18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on 18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was definitely established or excluded by appropriate viral testing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 30, 2020
• Est. primary completion date: June 30, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient coming to nuclear medicine for 18F-flurodesoxyglucose (FDG) positron emission tomography computed tomography (PET-CT) with suspicion of lung involvement

• patient affiliated to a social security scheme or equivalent

• adult patient having been informed of the study

Exclusion Criteria:

• patient with a negative covid 19 test

Related Conditions & MeSH terms

• Congenital Abnormalities
• Infection
• Presence of COVID-19 Compatible CT Abnormalities

Intervention

Diagnostic Test:
• PET-CT of 18F-FDG
Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)

Locations

Country	Name	City	State
France	CHRU of Nancy	Vandœuvre-lès-Nancy	Grand Est

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual analysis of pulmonary lobes	Visual analysis of the pulmonary lobes by calculating a extent score for each patient	1 day
Secondary	Measurement of metabolic activity	Measurement of metabolic activity with SUV max of lung areas with CT abnormalities	1 day